CGM Sensor Drift & Stability Patent Landscape 2026
The CGM sensor drift and stability space is highly concentrated, with Medtronic MiniMed, I-SENS, and Dexcom collectively anchoring the field; the top five filers account for two-thirds of the leading hundred filers’ combined output. Filing activity peaked in 2019 and the field is still expanding on a multi-year basis, though annual volume has eased from that peak, placing the technology in a post-peak maturation phase.
Medtronic MiniMed leads a tightly consolidated field
Medtronic MiniMed holds the top position with 141 patent records, nearly double the second-ranked I-SENS (73 patent records) and more than twice the third-ranked Dexcom (59 patent records). The top five filers’ share of the hundred largest filers’ combined total stands at 66%, confirming a strongly consolidated competitive structure.
A clear tier gap separates the top three from the rest: Abbott Diabetes Care (27 patent records) and Allez Health (15 patent records) trail at roughly one-fifth and one-tenth of the leader’s output, respectively. Below them, applicants cluster at single-digit or low-double-digit counts, indicating limited depth in the challenger tier.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic MiniMed Inc | 141 | |
| 2 | I-SENS Inc | 73 | |
| 3 | Dexcom Inc | 59 | |
| 4 | Abbott Diabetes Care Inc | 27 | |
| 5 | Allez Health Inc | 15 | |
| 6 | Ascensia Diabetes Care Holdings AG | 14 | |
| 7 | University of Virginia Patent Foundation | 12 | |
| 8 | F HOFFMANN LA ROCHE & CO AG | 10 | |
| 9 | Pacific Diabetes Technologies Inc | 9 | |
| 10 | Roche Diabetes Care Inc | 5 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Biolinq Inc | 5 | |
| 12 | Cercacor Laboratories Inc | 4 | |
| 13 | University of Padova | 4 | |
| 14 | Regents of the University of California | 4 | |
| 15 | Insulet Corporation | 4 | |
| 16 | Jiangsu Yuekai Biotechnology Co Ltd | 3 | |
| 17 | Willow Lab Inc | 3 | |
| 18 | The University of Hong Kong | 3 | |
| 19 | Roche Diagnostics GmbH | 3 | |
| 20 | Medtrum Technologies Inc | 3 |
Medtronic MiniMed’s commanding lead, stable recent momentum, and broad multi-class coverage suggest entrenched freedom-to-operate risk for new entrants working on core sensor correction and calibration methods. Challengers holding meaningful positions — I-SENS with wireless connectivity emphasis and Dexcom with healthcare informatics — reflect diversified but narrower strategic bets.
Filing counts for 2025 and 2026 are subject to publication lag and should be treated as partial; the apparent decline in those years does not necessarily reflect a real reduction in inventive activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2019 peak followed by stabilization, with sensor diagnostics dominating the technology mix
The annual filing trend reveals a sharp 2019 surge followed by a return to lower steady-state volumes, while the technology composition chart shows that sensor diagnosis and surgery (A61B) accounts for the dominant share of IPC coverage, with informatics and materials analysis serving as secondary branches.
Annual filing trend
Filings climbed from 23 in 2017 to a peak of 71 in 2019, then fell back to a range of 26–42 through 2021–2025. The 2025 and 2026 bars are materially under-counted due to publication lag and should not be read as continued decline. The multi-year window remains positive relative to 2017 levels.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & Surgery) dominates IPC coverage, reflecting the sensor hardware and measurement correction core of the field. G16H (Healthcare Informatics) and A61M (Devices for Body Fluids) form a second tier, capturing data management and delivery-system integration. Smaller branches including G01N (Material Analysis), G06F (Digital Data Processing), and G06N (AI Models) signal emerging interest in algorithmic drift correction and materials-level approaches.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Retrospective retrofitting method to generate a co…
Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycemic-regulation therapies. To define those outcome metrics… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Medical systems, devices and methods | 1,212 |
| 2 | Glucose sensors and methods of manufacturing | 294 |
| 3 | Systems and methods for leveraging smartphone feat… | 247 |
| 4 | Real time management of data relating to physiolog… | 232 |
| 5 | Orthogonally Redundant Sensor Systems and Methods | 230 |
| 6 | Systems and methods for health data visualization … | 162 |
| 7 | Systems and methods for leveraging smartphone feat… | 137 |
| 8 | Systems and methods for leveraging smartphone feat… | 90 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment
The combination of a past-peak lifecycle, high concentration, and limited collaboration creates a specific risk-opportunity profile: incremental improvements to established sensor platforms face dense prior art, while algorithmic and materials-level approaches remain comparatively open.
Post-peak field with stabilizing annual output
The lifecycle stage is classified as Decline, with annual filings easing back from the 2019 peak of 71. Multi-year filing volume remains above the 2017 baseline, indicating the field has not collapsed but is no longer in rapid expansion. R&D teams should treat core electrochemical correction approaches as mature prior-art territory and focus on differentiated sub-methods.
Lifecycle: DeclineTop three control the narrative; second tier is thin
The top five filers account for 66% of the hundred largest filers’ combined patent records, and the leader’s count (141) is nearly twice that of the second-ranked applicant (73). The gap between rank three (59) and rank four (27) is abrupt. This concentration means freedom-to-operate analysis must prioritize Medtronic MiniMed, I-SENS, and Dexcom portfolios before any development program begins.
High concentrationMinimal co-filing; one documented Roche cross-entity pair
The only identified co-filing relationship is between F. Hoffmann-La Roche and Roche Diagnostics GmbH, with 2 joint filings. This suggests the field is overwhelmingly prosecuted through single-applicant strategies, with no evidence of broad cross-industry consortia or university-industry joint programs. Collaborative entry routes are therefore largely uncontested.
Low collaborationUS-centric, with EPO and Australia as secondary markets
The United States leads jurisdictional coverage, followed by Europe via the EPO and Australia. PCT and Canada add meaningful breadth. China, Japan, and South Korea each have very limited coverage, representing potential enforcement gaps for non-US innovators. New entrants filing regionally in Asia may face lower opposition density.
US-led, Asia thinGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| F. Hoffmann-La Roche Ltd | Roche Diagnostics GmbH | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic MiniMed anchors the field; Dexcom and I-SENS hold differentiated positions
The top two players differ meaningfully in technical emphasis: Medtronic MiniMed spans sensor hardware, fluid delivery, and electrochemical analysis, while I-SENS concentrates on sensor diagnostics and wireless communication. Dexcom’s portfolio leans toward healthcare informatics and connected data management.
Medtronic MiniMed Inc
With 141 patent records, Medtronic MiniMed holds the largest position by a significant margin. Its technology focus spans A61B (sensor diagnosis), A61M (body fluid delivery devices), and G01N (electrochemical material analysis), indicating a vertically integrated approach from sensor chemistry to system integration. Recent momentum is flat at 0% versus the prior period, suggesting a portfolio in maintenance mode rather than active expansion.
Patent records: 141Dexcom Inc
Dexcom holds 59 patent records and is the third-ranked applicant. Its emphasis on G16H (Healthcare Informatics) alongside core A61B coverage differentiates it from hardware-focused rivals, reflecting a strategy centered on data interpretation and clinical decision support around sensor readings. Recent momentum shows a decline of 27% versus the prior period, indicating a slowdown in new filings in this sub-domain.
Patent records: 59| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic MiniMed Inc | 31 | ▬ 0% |
| I-SENS Inc | 9 | ▼ -85% |
| Dexcom Inc | 11 | ▼ -27% |
| Abbott Diabetes Care Inc | 1 | ▲ new entrant |
| Allez Health Inc | 6 | ▲ new entrant |
| University of Virginia Patent Foundation | 5 | ▲ new entrant |
Under-served routes in AI-driven correction and materials analysis
Several IPC branches adjacent to the dominant A61B core show comparatively sparse coverage, and at least two carry plausible technical value for next-generation drift compensation: algorithmic correction via AI models and electrochemical materials characterization.
G06N · AI-based drift correction models
G06N (Computing Based on AI Models) accounts for a relatively small share of the corpus. Given that sensor drift is fundamentally a time-series prediction and compensation problem, machine-learning and neural-network approaches to in-vivo calibration correction represent a technically credible and commercially relevant direction. The sparse coverage relative to the hardware-heavy A61B core suggests an entry path for teams with signal-processing or ML expertise, particularly in on-device inference for wearable constraints.
Search this in Eureka →G01N · Electrochemical material characterization
G01N (Material Analysis and Testing) carries a modest share of coverage despite being directly relevant to the root-cause characterization of enzyme degradation, membrane fouling, and interferent response — the primary physical mechanisms behind sensor drift. Work in this branch could address drift at the materials level rather than through post-hoc algorithmic correction, offering a differentiated and potentially more durable competitive position. Entry paths include novel membrane chemistries, enzyme immobilization techniques, and accelerated aging protocols.
Search this in Eureka →How top filers differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61B 5 · Diagnosis & surgery | A61M 5 · Devices for body fluids | G16H 40 · Healthcare informatics | G16H 50 · Healthcare informatics | G16H 20 · Healthcare informatics |
|---|---|---|---|---|---|
| Medtronic MiniMed Inc | Strong · 139 | Moderate · 42 | Emerging · 22 | Emerging · 22 | Emerging · 23 |
| Dexcom Inc | Strong · 56 | Absent | Moderate · 15 | Moderate · 14 | Emerging · 11 |
| Abbott Diabetes Care Inc | Strong · 27 | Strong · 20 | Strong · 15 | Strong · 15 | Strong · 15 |
| I-SENS Inc | Strong · 72 | Absent | Absent | Absent | Absent |
| University of Virginia Patent Foundation | Strong · 12 | Strong · 8 | Strong · 7 | Strong · 9 | Strong · 8 |
| F. Hoffmann-La Roche Ltd | Strong · 9 | Moderate · 3 | Moderate · 4 | Strong · 5 | Moderate · 3 |
| Ascensia Diabetes Care Holdings AG | Strong · 14 | Absent | Moderate · 4 | Emerging · 2 | Absent |
Frequently asked questions
Medtronic MiniMed Inc leads with 141 patent records, nearly double the second-ranked I-SENS Inc at 73 patent records. Together with Dexcom Inc (59), these three applicants dominate the field. The top five filers account for 66% of the hundred largest filers’ combined total, confirming high concentration.
Annual filings peaked in 2019 at 71 records, up from 23 in 2017. Volume subsequently fell back to a range of 26–42 annually through 2021–2025. The lifecycle is classified as Decline, meaning annual volume has eased from the 2019 peak, though multi-year activity remains above early-period levels. The 2025 and 2026 data are under-counted due to publication lag.
The United States is the leading jurisdiction by coverage, followed by Europe via the EPO and Australia. PCT and Canada add secondary breadth. China, Japan, and South Korea each have notably limited coverage in this specific corpus, which may represent enforcement gaps or under-filed geographies.
A61B (Diagnosis and Surgery) dominates the IPC composition, reflecting sensor hardware and measurement correction as the core focus. G16H (Healthcare Informatics) and A61M (Devices for Body Fluids) form a secondary tier. Smaller branches including G01N (Material Analysis), G06F (Digital Data Processing), and G06N (AI Models) indicate emerging interest in algorithmic and materials-level drift compensation.
Two adjacent branches stand out for their relatively sparse coverage combined with technical relevance: G06N (AI-based drift correction models) and G01N (electrochemical material characterization). Both address core mechanisms of sensor drift — time-series compensation and physical degradation — but carry lower current patent density than the dominant A61B hardware branch. These are observations of relative sparsity; commercial viability depends on technical and regulatory factors not captured in filing counts alone.
Collaboration is minimal. The only identified co-filing relationship in the evidence is between F. Hoffmann-La Roche and Roche Diagnostics GmbH, with 2 joint filings. The field is overwhelmingly prosecuted through single-applicant strategies, and there is no evidence of broad cross-industry consortia or substantial university-industry joint programs.
Ready to map your own CGM sensor drift landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.